IRISanRaf

PICCONI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.099
AS - Asia 3.220
EU - Europa 1.137
SA - Sud America 341
Continente sconosciuto - Info sul continente non disponibili 321
AF - Africa 76
OC - Oceania 16
Totale 10.210
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.637
TR - Turchia 951
SG - Singapore 895
CN - Cina 820
IT - Italia 573
CA - Canada 417
BR - Brasile 267
VN - Vietnam 180
CZ - Repubblica Ceca 120
DE - Germania 102
GB - Regno Unito 85
HK - Hong Kong 79
EU - Europa 67
BD - Bangladesh 64
IN - India 58
FR - Francia 53
IE - Irlanda 45
PK - Pakistan 34
MX - Messico 28
ZA - Sudafrica 27
NL - Olanda 25
AR - Argentina 21
JP - Giappone 21
CO - Colombia 19
RU - Federazione Russa 19
FI - Finlandia 18
IL - Israele 18
ES - Italia 16
PL - Polonia 15
EC - Ecuador 14
UA - Ucraina 14
ID - Indonesia 13
IQ - Iraq 12
MA - Marocco 10
RO - Romania 10
AU - Australia 9
SE - Svezia 9
SA - Arabia Saudita 8
JO - Giordania 7
PH - Filippine 7
CL - Cile 6
DK - Danimarca 6
KE - Kenya 6
MY - Malesia 6
NZ - Nuova Zelanda 6
SC - Seychelles 6
TW - Taiwan 6
DZ - Algeria 5
EG - Egitto 5
PS - Palestinian Territory 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
KR - Corea 4
NI - Nicaragua 4
PE - Perù 4
TN - Tunisia 4
VE - Venezuela 4
AL - Albania 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BE - Belgio 3
GR - Grecia 3
JM - Giamaica 3
NP - Nepal 3
OM - Oman 3
PY - Paraguay 3
RS - Serbia 3
SN - Senegal 3
BB - Barbados 2
BG - Bulgaria 2
CR - Costa Rica 2
IR - Iran 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
LT - Lituania 2
NG - Nigeria 2
UY - Uruguay 2
AT - Austria 1
BY - Bielorussia 1
CH - Svizzera 1
DJ - Gibuti 1
ET - Etiopia 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
KG - Kirghizistan 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
MR - Mauritania 1
MU - Mauritius 1
NO - Norvegia 1
PA - Panama 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.948
Salva come PNG Salva come JPEG
Città #
Kocaeli 807
San Mateo 688
San Jose 532
Toronto 375
Ashburn 373
Rome 343
Council Bluffs 320
Dallas 285
Singapore 262
Wilmington 203
Beijing 187
Houston 183
Santa Clara 181
Phoenix 168
Chandler 159
Princeton 146
Lawrence 139
Olomouc 119
Fairfield 84
Hong Kong 75
Ho Chi Minh City 64
Shanghai 61
Seattle 52
Los Angeles 50
Woodbridge 48
Hanoi 43
Guangzhou 37
Munich 35
Redwood City 34
Chicago 33
São Paulo 30
Islamabad 27
New York 27
The Dalles 25
Columbus 23
Dublin 23
Shenzhen 23
Cambridge 22
Frankfurt am Main 22
Brooklyn 21
Falls Church 19
Boston 16
Chennai 16
Orem 16
Tokyo 16
Jiaxing 15
London 15
Mexico City 15
Netanya 15
Johannesburg 14
Milan 14
Helsinki 13
Pune 12
Abbeville 11
Belo Horizonte 11
Ningbo 11
Wuhan 11
Constanta 10
Buffalo 9
Charlotte 9
Montreal 9
Rio de Janeiro 9
Dhaka 8
Guayaquil 8
Mumbai 8
Stockholm 8
Amman 7
Bogotá 7
Florence 7
Haiphong 7
Rui'an 7
Wroclaw 7
Amsterdam 6
Bristol 6
Cagliari 6
Da Nang 6
Dongyang 6
Philadelphia 6
Trento 6
Washington 6
Wuxi 6
Atlanta 5
Biên Hòa 5
Guarulhos 5
Haining 5
Jakarta 5
Manaus 5
Medellín 5
Nairobi 5
Padova 5
Paris 5
Saint Louis 5
Tashkent 5
Warsaw 5
Ankara 4
Boardman 4
Casablanca 4
Curitiba 4
Espoo 4
Genoa 4
Totale 6.832
Salva come PNG Salva come JPEG
Nome #
Direct and indirect pathways of basal ganglia: a critical reappraisal 247
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 158
A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation 132
Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons 109
Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease 109
Corrigendum: Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons 108
Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. 100
Quantal release of dopamine and action potential firing detected in midbrain neurons by multifunctional diamond-based microarrays 100
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. 92
Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. 91
New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease 90
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. 89
BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior 89
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuo-spatial memory alteration. 89
Synaptic dysfunction in Parkinson's disease 85
Dopamine drives binge-like consumption of a palatable food in experimental parkinsonism. 85
Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission 85
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 84
Interaction between basal ganglia and limbic circuits in learning and memory processes 83
A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. 81
Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit 81
Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease 81
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. 80
A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity 78
Striatal spreading depolarization: possible implication in L-DOPA-induced dyskinetic like-behavior. 77
Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum 77
Neuroinflammation and Dyskinesia: A Possible Causative Relationship? 76
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap 76
Motor Complications in Parkinson's Disease: Striatal Molecular and Electrophysiological Mechanisms of Dyskinesias 76
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities 75
Serotonin drives striatal synaptic plasticity in a sex-related manner 75
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 74
NMDA receptor G1uN2D subunit participates to levodopa-induced dyskinesia pathophysiology 74
Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine 73
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts 73
An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease 73
Role of tonically-active neurons in the control of striatal function: Cellular mechanisms and behavioral correlates 72
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias 72
The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D-2/A(2A) Receptor Interaction in the Striatum: Implications for Parkinson's Disease 72
A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication 71
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. 71
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia 71
Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors 71
Theta-burst stimulation and striatal plasticity in experimental parkinsonism 70
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias 70
Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment 70
N-Methyl-D-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons 70
Dopaminergic control of synaptic plasticity in the dorsal striatum 69
Dopamine-mediated regulation of corticostriatal synaptic plasticity. 69
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of L-Dopa-induced dyskinesia 68
Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. 68
L-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via beta-adrenergic receptors 68
Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine 68
Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease 68
Transcranial Magnetic Stimulation Exerts "Rejuvenation" Effects on Corticostriatal Synapses after Partial Dopamine Depletion 68
Intensive exercise ameliorates motor and cognitive symptoms in experimental Parkinson's disease restoring striatal synaptic plasticity 68
Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice 67
Striatum-hippocampus balance: From physiological behavior to interneuronal pathology 67
Prenatal stress and hippocampal BDNF expression: a fading imperative 67
Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. 67
NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. 66
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 66
Early Synaptic Dysfunction in Parkinson's Disease: Insights From Animal Models 66
Dopamine denervation induces neurotensin immunoreactivity in GABA-parvalbumin striatal neurons 66
Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons 66
Mechanisms underlying dopaminergic control of cortico-striatal synaptic transmission 65
Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum 65
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission 65
Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. 65
Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia 64
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia 64
Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression 64
New Synaptic and Molecular Targets for Neuroprotection in Parkinson's Disease 64
Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease 63
Hyperkinetic disorders and loss of synaptic downscaling 63
Dopamine-dependent early synaptic and motor dysfunctions induced by a-synuclein in the nigrostriatal circuit 62
NR2B subunit exerts a critical role in postischemic synaptic plasticity. 62
Unilateral dopamine denervation blocks corticostriatal LTP 62
Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice 62
Neural networks and synaptic plasticity in Parkinson's disease: beyond motor deficits 62
Critical role of calcitonin gene-related peptide receptors in cortical spreading depression 62
Tissue plasminogen activator is required for corticostriatal long-term potentiation 61
FUNCTIONAL INTERACTIONS WITHIN STRIATAL MICROCIRCUIT IN ANIMAL MODELS OF HUNTINGTON'S DISEASE 61
Rhes-mTORC1 interaction: A new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia? 61
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. 61
mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP 61
Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors 61
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. 61
Basic mechanisms of plasticity and learning 60
Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission 60
Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. 60
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism 60
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? 59
Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition 59
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia 59
Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia 59
Plastic abnormalities in experimental Huntington's disease 59
From cell lines to pluripotent stem cells for modelling Parkinson's Disease 59
Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity 58
Plasticity and repair in the post-ischemic brain. 58
Totale 7.468
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.043
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.043
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022969 0 0 372 1 9 12 89 139 36 279 11 21
2022/2023647 308 15 13 54 33 16 5 21 29 63 82 8
2023/2024571 0 2 17 127 26 17 15 37 3 21 70 236
2024/20251.466 54 338 98 68 92 234 41 98 191 20 58 174
2025/20263.286 258 244 298 236 231 382 490 249 275 454 79 90
2026/2027905 58 361 486 0 0 0 0 0 0 0 0 0
Totale 10.210